Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 7.85% in after-hours trading on October 28, 2024, after the medical device company reported strong third-quarter results and raised its full-year revenue guidance.

For the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, up 21.4% year-over-year, surpassing analysts' expectations of $150.7 million. The company attributed the growth to an expansion in its sales territories, opening of new accounts, increased adoption of its procedures, global commercial expansion, and the introduction of new products.

While Inari Medical reported a GAAP operating loss of $13.6 million, its non-GAAP operating loss improved sequentially to $0.4 million, compared to a non-GAAP operating income of $4.8 million in the same period last year. The company expects to achieve sustained operating profitability in the first half of 2025.